Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 589.2 DKK -20.72% Market Closed
Market Cap: 2.6T DKK
Have any thoughts about
Novo Nordisk A/S?
Write Note

Novo Nordisk A/S
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Novo Nordisk A/S
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Novo Nordisk A/S
CSE:NOVO B
Total Receivables
kr79.6B
CAGR 3-Years
31%
CAGR 5-Years
25%
CAGR 10-Years
17%
H Lundbeck A/S
CSE:HLUN A
Total Receivables
kr3.6B
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ALK-Abello A/S
CSE:ALK B
Total Receivables
kr924m
CAGR 3-Years
11%
CAGR 5-Years
12%
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Total Receivables
kr3.7m
CAGR 3-Years
36%
CAGR 5-Years
4%
CAGR 10-Years
N/A
No Stocks Found

Novo Nordisk A/S
Glance View

Market Cap
2.6T DKK
Industry
Pharmaceuticals
Economic Moat
Wide

In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.

NOVO B Intrinsic Value
683.36 DKK
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Novo Nordisk A/S's Total Receivables?
Total Receivables
79.6B DKK

Based on the financial report for Sep 30, 2024, Novo Nordisk A/S's Total Receivables amounts to 79.6B DKK.

What is Novo Nordisk A/S's Total Receivables growth rate?
Total Receivables CAGR 10Y
17%

Over the last year, the Total Receivables growth was 29%. The average annual Total Receivables growth rates for Novo Nordisk A/S have been 31% over the past three years , 25% over the past five years , and 17% over the past ten years .

Back to Top